表观遗传疗法作为克服上皮性卵巢癌化疗耐药的一种有前景的策略。
Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer.
作者信息
Suh Dong Hoon, Kim Mi-Kyung, Kim Hee Seung, Chung Hyun Hoon, Song Yong Sang
机构信息
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam.
Department of Obstetrics and Gynecology, Seoul National University College of Medicine.
出版信息
J Cancer Prev. 2013 Sep;18(3):227-34. doi: 10.15430/jcp.2013.18.3.227.
Over the past decades, prognosis of advanced stage epithelial ovarian cancer remains very poor, despite the development of new chemotherapeutic drugs, as well as molecular targeted agents. Late presentation and frequent chemoresistance account for the poor prognosis. Emerging studies have shown that many genetic changes, especially p53 mutation, are associated with the chemoresistance. However, recent failure of the clinical trials using p53 gene-therapy makes researchers discuss the possible reasons for the failure. Epigenetic changes are considered one of the substantial reasons. Successful restoration of the aberrant epigenetic changes may be a promising strategy for overcoming chemoresistance in epithelial ovarian cancer. Herein, we will summarize the rationale for epigenetic therapy of cancer and current status of epigenetic studies in relation to chemoresistance in epithelial ovarian cancer.
在过去几十年里，尽管开发了新的化疗药物以及分子靶向药物，但晚期上皮性卵巢癌的预后仍然很差。就诊延迟和频繁的化疗耐药是导致预后不良的原因。新兴研究表明，许多基因改变，尤其是p53突变，与化疗耐药有关。然而，最近使用p53基因治疗的临床试验失败，促使研究人员探讨失败的可能原因。表观遗传改变被认为是一个重要原因。成功恢复异常的表观遗传改变可能是克服上皮性卵巢癌化疗耐药的一种有前景的策略。在此，我们将总结癌症表观遗传治疗的基本原理以及与上皮性卵巢癌化疗耐药相关的表观遗传学研究现状。
Zotero 插件